GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Outset Medical Inc (NAS:OM) » Definitions » Net Income

Outset Medical (Outset Medical) Net Income : $-168.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Outset Medical Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Outset Medical's Net Income for the three months ended in Mar. 2024 was $-39.9 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-168.8 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Outset Medical's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.78.


Outset Medical Net Income Historical Data

The historical data trend for Outset Medical's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outset Medical Net Income Chart

Outset Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial -68.30 -121.49 -131.94 -162.96 -172.80

Outset Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.97 -44.05 -46.18 -38.60 -39.94

Outset Medical Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Outset Medical's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-172.274+-0.523+0+0
=-172.8

Outset Medical's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-39.782+-0.162+0+-7.105427357601E-15
=-39.9

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-168.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outset Medical  (NAS:OM) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Outset Medical's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Outset Medical Net Income Related Terms

Thank you for viewing the detailed overview of Outset Medical's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Outset Medical (Outset Medical) Business Description

Traded in Other Exchanges
N/A
Address
3052 Orchard Drive, San Jose, CA, USA, 95134
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
Executives
Leslie Trigg director, officer: President & CEO C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Marc Nash officer: SVP, Operations and R&D 3052 ORCHARD DRIVE, SAN JOSE CA 95134
Jean-olivier Racine officer: Chief Technology Officer 3052 ORCHARD DRIVE, SAN JOSE CA 95134
Nabeel Ahmed officer: Interim CFO 3052 ORCHARD DRIVE, SAN JOSE CA 95134
Stacey L. Porter officer: Chief People Officer 3052 ORCHARD DRIVE, SAN JOSE CA 95134
John L. Brottem officer: General Counsel 3052 ORCHARD DR., SAN JOSE CA 95134
Steven S. Williamson officer: Chief Commercial Officer C/O HOLOGIC, INC., BEDFORD MA 01730
Martin Vazquez officer: Chief Operating Officer 3052 ORCHARD DR., SAN JOSE CA 95134
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Dale E Jones director C/O HUGHES SUPPLY INC, 20 N ORANGE AVE, ORLANDO FL 32801
D Keith Grossman director
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Warburg Pincus Llc director, 10 percent owner 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017